Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania

Rosanne C. State, Mark A Frye, Lori L. Altshuler, Michael Strober, Mark DeAntonio, Sun Hwang, Jim Mintz

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: Although adolescent onset of bipolar disorder is common, the optimal treatment approach for mania in this age group remains understudied. Comorbid attention-deficit/hyperactivity disorder (ADHD) has been reported to predict lithium resistance in adolescents with bipolar disorder. Little is known about response to divalproex sodium in adolescents with bipolar disorder comorbid with ADHD. This study was conducted to evaluate comparative response rates to lithium and divalproex sodium in adolescent mania with and without this comorbidity. Method: Medical records were reviewed for 42 patients (ages 12-19 years) who were hospitalized for acute mania and discharged with a diagnosis of DSM-III-R or DSM-IV bipolar disorder on either lithium (N = 29) or divalproex sodium (N = 13) treatment. A clinician blinded to treatment status rated improvement on the basis of abstracted notes in each case utilizing the Clinical Global Impressions Scale modified for use in bipolar illness (CGI-BP). Response was defined as a discharge CGI-BP overall change score of 1 or 2 (much or very much improved). Data were collected from January 1992 through May 1999. Results: 36/42 (85.7%) patients presented with mixed mania, and 14/41 (34.1%) patients had a history of ADHD. The overall response rate was 80.9% (34/42). 92.6% (25/27) of patients without ADHD were responders versus 57.1% (8/14) of subjects with comorbid ADHD (p = .007). There were no significant differences in response rates for lithium versus divalproex sodium in subjects with and without ADHD. Conclusion: These retrospective data suggest overall equivalent response rates for lithium and divalproex sodium in predominantly mixed adolescent mania. However, a history of ADHD was associated with a significantly diminished acute response to both divalproex sodium and lithium as a primary treatment for the manic phase of bipolar disorder.

Original languageEnglish (US)
Pages (from-to)1057-1063
Number of pages7
JournalJournal of Clinical Psychiatry
Volume65
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Valproic Acid
Attention Deficit Disorder with Hyperactivity
Bipolar Disorder
Lithium
Comorbidity
Diagnostic and Statistical Manual of Mental Disorders
Therapeutics
Medical Records
Age Groups

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. / State, Rosanne C.; Frye, Mark A; Altshuler, Lori L.; Strober, Michael; DeAntonio, Mark; Hwang, Sun; Mintz, Jim.

In: Journal of Clinical Psychiatry, Vol. 65, No. 8, 08.2004, p. 1057-1063.

Research output: Contribution to journalArticle

State, Rosanne C. ; Frye, Mark A ; Altshuler, Lori L. ; Strober, Michael ; DeAntonio, Mark ; Hwang, Sun ; Mintz, Jim. / Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. 8. pp. 1057-1063.
@article{d10e5a323a9a43ceab18da644bf0c8aa,
title = "Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania",
abstract = "Purpose: Although adolescent onset of bipolar disorder is common, the optimal treatment approach for mania in this age group remains understudied. Comorbid attention-deficit/hyperactivity disorder (ADHD) has been reported to predict lithium resistance in adolescents with bipolar disorder. Little is known about response to divalproex sodium in adolescents with bipolar disorder comorbid with ADHD. This study was conducted to evaluate comparative response rates to lithium and divalproex sodium in adolescent mania with and without this comorbidity. Method: Medical records were reviewed for 42 patients (ages 12-19 years) who were hospitalized for acute mania and discharged with a diagnosis of DSM-III-R or DSM-IV bipolar disorder on either lithium (N = 29) or divalproex sodium (N = 13) treatment. A clinician blinded to treatment status rated improvement on the basis of abstracted notes in each case utilizing the Clinical Global Impressions Scale modified for use in bipolar illness (CGI-BP). Response was defined as a discharge CGI-BP overall change score of 1 or 2 (much or very much improved). Data were collected from January 1992 through May 1999. Results: 36/42 (85.7{\%}) patients presented with mixed mania, and 14/41 (34.1{\%}) patients had a history of ADHD. The overall response rate was 80.9{\%} (34/42). 92.6{\%} (25/27) of patients without ADHD were responders versus 57.1{\%} (8/14) of subjects with comorbid ADHD (p = .007). There were no significant differences in response rates for lithium versus divalproex sodium in subjects with and without ADHD. Conclusion: These retrospective data suggest overall equivalent response rates for lithium and divalproex sodium in predominantly mixed adolescent mania. However, a history of ADHD was associated with a significantly diminished acute response to both divalproex sodium and lithium as a primary treatment for the manic phase of bipolar disorder.",
author = "State, {Rosanne C.} and Frye, {Mark A} and Altshuler, {Lori L.} and Michael Strober and Mark DeAntonio and Sun Hwang and Jim Mintz",
year = "2004",
month = "8",
doi = "10.4088/JCP.v65n0805",
language = "English (US)",
volume = "65",
pages = "1057--1063",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania

AU - State, Rosanne C.

AU - Frye, Mark A

AU - Altshuler, Lori L.

AU - Strober, Michael

AU - DeAntonio, Mark

AU - Hwang, Sun

AU - Mintz, Jim

PY - 2004/8

Y1 - 2004/8

N2 - Purpose: Although adolescent onset of bipolar disorder is common, the optimal treatment approach for mania in this age group remains understudied. Comorbid attention-deficit/hyperactivity disorder (ADHD) has been reported to predict lithium resistance in adolescents with bipolar disorder. Little is known about response to divalproex sodium in adolescents with bipolar disorder comorbid with ADHD. This study was conducted to evaluate comparative response rates to lithium and divalproex sodium in adolescent mania with and without this comorbidity. Method: Medical records were reviewed for 42 patients (ages 12-19 years) who were hospitalized for acute mania and discharged with a diagnosis of DSM-III-R or DSM-IV bipolar disorder on either lithium (N = 29) or divalproex sodium (N = 13) treatment. A clinician blinded to treatment status rated improvement on the basis of abstracted notes in each case utilizing the Clinical Global Impressions Scale modified for use in bipolar illness (CGI-BP). Response was defined as a discharge CGI-BP overall change score of 1 or 2 (much or very much improved). Data were collected from January 1992 through May 1999. Results: 36/42 (85.7%) patients presented with mixed mania, and 14/41 (34.1%) patients had a history of ADHD. The overall response rate was 80.9% (34/42). 92.6% (25/27) of patients without ADHD were responders versus 57.1% (8/14) of subjects with comorbid ADHD (p = .007). There were no significant differences in response rates for lithium versus divalproex sodium in subjects with and without ADHD. Conclusion: These retrospective data suggest overall equivalent response rates for lithium and divalproex sodium in predominantly mixed adolescent mania. However, a history of ADHD was associated with a significantly diminished acute response to both divalproex sodium and lithium as a primary treatment for the manic phase of bipolar disorder.

AB - Purpose: Although adolescent onset of bipolar disorder is common, the optimal treatment approach for mania in this age group remains understudied. Comorbid attention-deficit/hyperactivity disorder (ADHD) has been reported to predict lithium resistance in adolescents with bipolar disorder. Little is known about response to divalproex sodium in adolescents with bipolar disorder comorbid with ADHD. This study was conducted to evaluate comparative response rates to lithium and divalproex sodium in adolescent mania with and without this comorbidity. Method: Medical records were reviewed for 42 patients (ages 12-19 years) who were hospitalized for acute mania and discharged with a diagnosis of DSM-III-R or DSM-IV bipolar disorder on either lithium (N = 29) or divalproex sodium (N = 13) treatment. A clinician blinded to treatment status rated improvement on the basis of abstracted notes in each case utilizing the Clinical Global Impressions Scale modified for use in bipolar illness (CGI-BP). Response was defined as a discharge CGI-BP overall change score of 1 or 2 (much or very much improved). Data were collected from January 1992 through May 1999. Results: 36/42 (85.7%) patients presented with mixed mania, and 14/41 (34.1%) patients had a history of ADHD. The overall response rate was 80.9% (34/42). 92.6% (25/27) of patients without ADHD were responders versus 57.1% (8/14) of subjects with comorbid ADHD (p = .007). There were no significant differences in response rates for lithium versus divalproex sodium in subjects with and without ADHD. Conclusion: These retrospective data suggest overall equivalent response rates for lithium and divalproex sodium in predominantly mixed adolescent mania. However, a history of ADHD was associated with a significantly diminished acute response to both divalproex sodium and lithium as a primary treatment for the manic phase of bipolar disorder.

UR - http://www.scopus.com/inward/record.url?scp=4544382889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544382889&partnerID=8YFLogxK

U2 - 10.4088/JCP.v65n0805

DO - 10.4088/JCP.v65n0805

M3 - Article

C2 - 15323589

AN - SCOPUS:4544382889

VL - 65

SP - 1057

EP - 1063

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -